{Reference Type}: Case Reports
{Title}: A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report.
{Author}: Chen X;Shi Z;Wang R;Zhou H;
{Journal}: Ther Adv Neurol Disord
{Volume}: 17
{Issue}: 0
{Year}: 2024
{Factor}: 6.43
{DOI}: 10.1177/17562864241258787
{Abstract}: Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD). It is a humanized monoclonal antibody targeting cluster of differentiation 19 (CD19). Common adverse reactions include urinary tract infections, nasopharyngitis, arthralgia, infusion reactions, headaches and a decrease in immunoglobulin levels. Here, we present a case of an NMOSD patient who experienced transient hyperCKaemia after the use of inebilizumab. The adverse reactions of this very rare monoclonal antibody drug improved after discontinuation.